Yahoo Finance Site Map
ArticlesFor a comprehensive guide to our content, please see the Site Index
SiteMap 2024 > 03 > 17
Other dates of the month:
- Cardinal Energy Full Year 2023 Earnings: EPS Misses Expectations
- EverGen Infrastructure Corp. (CVE:EVGN) On The Verge Of Breaking Even
- 15 US Bucket List Trips In 2024 For Adventure Lovers
- Are Homebuyers Hit Hardest By Landmark Realtor Lawsuit?
- LGI Homes (NASDAQ:LGIH) sheds 4.4% this week, as yearly returns fall more in line with earnings growth
- The Best Warren Buffett Stocks to Buy With $300 Right Now
- Best Buy (NYSE:BBY) Is Increasing Its Dividend To $0.94
- 20 Most Visited Cities in the US by Foreign Travelers
- TransAlta (TSE:TA investor three-year losses grow to 19% as the stock sheds CA$252m this past week
- G-III Apparel Group, Ltd. (NASDAQ:GIII) Just Released Its Full-Year Earnings: Here's What Analysts Think
- Where Will Viking Therapeutics Be in 5 Years?
- Choice Hotels International (NYSE:CHH) Has Announced A Dividend Of $0.2875
- One Galantas Gold Insider Raised Stake By 3,903% In Previous Year
- Citizens & Northern Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
- The total return for Enova International (NYSE:ENVA) investors has risen faster than earnings growth over the last five years
- Netanyahu snaps back against growing US criticism after being accused of losing his way on Gaza
- A Groundbreaking Milestone in the Treatment of NASH and Liver Fibrosis - Anervea
- Autolus Therapeutics plc (NASDAQ:AUTL) Q4 2023 Earnings Call Transcript
- Can Betterware de México, S.A.P.I. de C.V.'s (NASDAQ:BWMX) ROE Continue To Surpass The Industry Average?
- Is Ameren Corporation's (NYSE:AEE) 10% ROE Strong Compared To Its Industry?
- Dollar General Corporation (NYSE:DG) Q4 2023 Earnings Call Transcript
- Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$4.33
- Bearish: Analysts Just Cut Their FTC Solar, Inc. (NASDAQ:FTCI) Revenue and EPS estimates
- Investors Met With Slowing Returns on Capital At Gilat Satellite Networks (NASDAQ:GILT)
- DICK’S Sporting Goods, Inc. (NYSE:DKS) Q4 2023 Earnings Call Transcript
- Want the Max $4,873 Social Security Benefit? Here's the Salary You Need
- Burlington Stores Full Year 2024 Earnings: EPS Beats Expectations
- Those who invested in VOXX International (NASDAQ:VOXX) five years ago are up 73%
- US$16.00: That's What Analysts Think Katapult Holdings, Inc. (NASDAQ:KPLT) Is Worth After Its Latest Results
- Smartsheet Inc. (NYSE:SMAR) Q4 2024 Earnings Call Transcript
- Is Crane Company's (NYSE:CR) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
- Turning Point Brands (NYSE:TPB) Is Increasing Its Dividend To $0.07
- Intel Who? Underdog AMD Stock’s 2,130% Surge Isn’t Over Yet.
- US$20.85: That's What Analysts Think KE Holdings Inc. (NYSE:BEKE) Is Worth After Its Latest Results
- How Did Abacus Life, Inc.'s (NASDAQ:ABL) 15% ROE Fare Against The Industry?
- Perma-Fix Environmental Services, Inc. (NASDAQ:PESI) Q4 2023 Earnings Call Transcript
- Could Every "Magnificent Seven" Stock Be in The Dow Jones Industrial Average by 2030?
- There’s an Opportunity Brewing in These 3 Industrial Stocks, Says Top Wall Street Analyst
- Oil mergers, clean fuels vie for attention at Houston energy conference
- Here's Why We're A Bit Worried About Lithium Americas' (TSE:LAC) Cash Burn Situation
- From Frenchies to rescue cats, New York's trauma center for animals takes the most complex cases
- UiPath Inc. (NYSE:PATH) Q4 2024 Earnings Call Transcript
- Howmet Aerospace's (NYSE:HWM) investors will be pleased with their enviable 367% return over the last five years
- Novo Nordisk Is Already Working on Wegovy's Successor -- Time to Buy?
- US$2.85 - That's What Analysts Think Blend Labs, Inc. (NYSE:BLND) Is Worth After These Results
- Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) market cap decline of US$89m may not have as much of an impact on institutional owners after a year of 1.4% returns
- Dollar Tree, Inc. (NASDAQ:DLTR) Q4 2023 Earnings Call Transcript
- 2 No-Brainer Healthcare Stocks to Buy With $1,000 Right Now
- This AVITA Medical Insider Increased Their Holding By 250% Last Year
- Arcturus Therapeutics Holdings Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag